Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445)

Urology. 2010 Oct;76(4):1020. doi: 10.1016/j.urology.2010.06.059.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / drug therapy*
  • Aged
  • Androgen Antagonists / adverse effects*
  • Androgen Antagonists / therapeutic use
  • Anemia / chemically induced*
  • Anemia / drug therapy
  • Anemia / physiopathology
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Erythrocyte Count*
  • Erythropoiesis / drug effects*
  • Erythropoietin / physiology
  • Erythropoietin / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / physiology*
  • Male
  • Middle Aged
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Receptor, IGF Type 1 / physiology*
  • Recombinant Proteins
  • Testosterone / deficiency
  • Testosterone / physiology

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Recombinant Proteins
  • Erythropoietin
  • Testosterone
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1